SCHEDULE 13D/A: Enavate Sciences Increases Stake in Immunome, Inc. to 6.0% Following Public Offering

Immunome Aggregator, LP, an entity managed by Enavate Sciences GP, LLC, has significantly increased its beneficial ownership in Immunome, Inc. to 6.0% through a recent purchase of shares in the Issuer's 2025 public offering.

Summary

• Immunome Aggregator, LP and Enavate Sciences GP, LLC (collectively, the "Reporting Entities") filed an Amendment No. 1 to their Schedule 13D regarding their beneficial ownership of Immunome, Inc. Common Stock.
• On January 31, 2025, Immunome Aggregator, LP purchased 1,290,322 shares of Common Stock from the underwriters of Immunome, Inc.'s public offering.
• The purchase price for these shares was $7.75 per share, totaling an aggregate of $9,999,995.50.
• The funds for this acquisition were sourced from capital contributions by Immunome Aggregator, LP's general and limited partners.
• Following this transaction, the Reporting Entities collectively beneficially own 4,768,583 shares of Immunome, Inc. Common Stock.
• This aggregate amount represents 6.0% of Immunome, Inc.'s outstanding common stock, based on 79,776,901 shares outstanding as of January 31, 2024.
• The Reporting Entities expressly disclaim status as a "group" for purposes of this Schedule 13D.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. A significant increase in ownership by an institutional investor, especially as part of a public offering, generally indicates confidence in the company's prospects and provides capital to the issuer.

Positives

• A significant increase in beneficial ownership by an institutional investor like Immunome Aggregator, LP, managed by Enavate Sciences GP, LLC, can signal confidence in Immunome, Inc.'s future prospects.
• The investment of nearly $10 million in the public offering demonstrates a substantial financial commitment from the Reporting Entities.

Management Comments

• James P. Boylan, Manager of Enavate Sciences GP, LLC, signed the Joint Filing Agreement and the Schedule 13D/A on behalf of both Immunome Aggregator, LP and Enavate Sciences GP, LLC, certifying the information as true, complete, and correct to his knowledge and belief.

Industry Context

This filing reflects an ongoing trend of venture capital and investment firms taking significant stakes in publicly traded biotechnology companies, often participating in public offerings to support growth and strategic initiatives. Such investments can provide capital for research and development, clinical trials, or commercialization efforts within the life sciences sector.

Legal Proceedings

• The Reporting Entities affirmed that during the last five years, none of them have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
• The Reporting Entities also affirmed that during the last five years, none of them have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction or were subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be viewed positively, potentially enhancing market confidence and liquidity.
• Immunome, Inc.: The company successfully raised capital through its public offering, with a significant portion purchased by Immunome Aggregator, LP, providing funds for its operations and strategic initiatives.

Key Dates

Keywords

Immunome Inc., Schedule 13D/A, beneficial ownership, Enavate Sciences, Immunome Aggregator LP, stock purchase, public offering, biotechnology investment, institutional investment